EGFR and neoplasm: Acquired resistance typically arises through a variety of mechanisms, including secondary mutations and persistent EGFR activation, alterations in downstream signaling pathways, phenotypic transformations, modifications in the tumor microenvironment, and immune dysregulation [6,7,8].